Shengming Kexue · Jun 2026
Systemic association between aging and Alzheimer′s disease: From shared mechanisms to multi-target interventions
By Jiang Q, WANG YJ
<?A3B2 tlsb=-.01w?>With the accelerating trend of population aging, the burden of Alzheimer′s disease (AD) continues to rise. Current disease-modifying therapies that target β-amyloid (Aβ) have demonstrated clear biological efficacy in clearing cerebral Aβ plaques; however, their ability to delay overall cognitive decline remains limited, and the clinical benefits have not yet reached the anticipated threshold. This discrepancy underscores the urgent need to develop systemic prevention and treatment paradigms that transcend single-target approaches and enable multi-level intervention. Aging, the predominant risk factor for AD, drives disease initiation and progression through multi-layered mechanisms, including disruption of molecular homeostasis, cellular functional decline, and systemic regulatory dysregulation. Collectively, these age-dependent changes establish a permissive microenvironment that substantially lowers the threshold for neurodegeneration. Within the brain, aging drives a cascade of interrelated pathological processes, including elevated oxidative stress, aberrant activation of microglia and astrocytes, and sustained neuroinflammation. Critically, it also directly promotes abnormal aggregation of pathogenic proteins. The brain is not an anatomically isolated organ; rather, its structural integrity, functional homeostasis, and adaptive plasticity are dynamically regulated by systemic signaling networks emanating from peripheral organs. Peripheral aging further accelerates brain aging through the “body–brain axis” interaction network: age-related deterioration of the cardiovascular system and skeletal muscle directly elevates the biological age of the brain. Furthermore, peripheral aging disrupts central Aβ metabolic homeostasis—not only by increasing Aβ production (driven in part by platelet hyperactivation and gut dysbiosis) but also by impairing Aβ clearance mechanisms, particularly those mediated by the liver and kidney. In addition, systemic comorbidities such as obesity and hypertension further aggravate AD-related neuropathology and heighten disease susceptibility. Given the complex and multi-layered interplay between aging and AD, this review advocates for a paradigm shift in future preventive and therapeutic strategies toward an integrative and coordinated framework. This framework comprises three core pillars: intervention on pathological events (clearing pathological proteins and blocking associated cascades), systemic rejuvenation (ameliorating comorbid factors and decelerating the aging background), and neuroprotection and brain network remodeling (enhancing neuronal resilience and rebuilding brain networks). This multi-pronged strategy simultaneously addresses the upstream aging drivers and the downstream pathological consequences. Such a multimodal, dynamically adjustable approach not only provides a solid theoretical foundation and a translational pathway for overcoming existing therapeutic bottlenecks, but also establishes a scientific basis and practical direction for achieving comprehensive life-course prevention and control, precision management of AD, and supporting national strategic goals for healthy aging.